Skip to Content
Merck
  • Protein kinase C fusion proteins are paradoxically loss of function in cancer.

Protein kinase C fusion proteins are paradoxically loss of function in cancer.

The Journal of biological chemistry (2021-02-23)
An-Angela N Van, Maya T Kunkel, Timothy R Baffi, Gema Lordén, Corina E Antal, Sourav Banerjee, Alexandra C Newton
ABSTRACT

Within the AGC kinase superfamily, gene fusions resulting from chromosomal rearrangements have been most frequently described for protein kinase C (PKC), with gene fragments encoding either the C-terminal catalytic domain or the N-terminal regulatory moiety fused to other genes. Kinase fusions that eliminate regulatory domains are typically gain of function and often oncogenic. However, several quality control pathways prevent accumulation of aberrant PKC, suggesting that PKC fusions may paradoxically be loss of function. To explore this topic, we used biochemical, cellular, and genome editing approaches to investigate the function of fusions that retain the portion of the gene encoding either the catalytic domain or regulatory domain of PKC. Overexpression studies revealed that PKC catalytic domain fusions were constitutively active but vulnerable to degradation. Genome editing of endogenous genes to generate a cancer-associated PKC fusion resulted in cells with detectable levels of fusion transcript but no detectable protein. Hence, PKC catalytic domain fusions are paradoxically loss of function as a result of their instability, preventing appreciable accumulation of protein in cells. Overexpression of a PKC regulatory domain fusion suppressed both basal and agonist-induced endogenous PKC activity, acting in a dominant-negative manner by competing for diacylglycerol. For both catalytic and regulatory domain fusions, the PKC component of the fusion proteins mediated the effects of the full-length fusions on the parameters examined, suggesting that the partner protein is dispensable in these contexts. Taken together, our findings reveal that PKC gene fusions are distinct from oncogenic fusions and present a mechanism by which loss of PKC function occurs in cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Gadolinium(III) oxide, powder, ≥99.99% trace metals basis
Sigma-Aldrich
Anti-α-Tubulin antibody, Mouse monoclonal, clone B-5-1-2, purified from hybridoma cell culture
Sigma-Aldrich
Etoposide, A cell-permeable derivative of podophyllotoxin that acts as a topoisomerase II inhibitor (IC₅₀ = 59.2 µM) has major activity against a number of tumors, including germ cell neoplasms, small cell lung cancer, and malignant lymphoma.
Sigma-Aldrich
Phorbol-12,13-dibutyrate, Strong irritant for mouse skin, but only moderately active as a tumor promoter.
Sigma-Aldrich
Gö 6976, InSolution, ≥95%, Inhibitor of protein kinase C
Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-74, purified immunoglobulin, buffered aqueous solution